Full Transcript: Johnson & Johnson Q2 2026 Earnings Call

Johnson & Johnson (NYSE: JNJ ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation.

3 billion, and raised full-year revenue guidance to exceed $100 billion. The company highlighted significant growth in its Innovative Medicine segment, particularly in oncology, immunology, and neuroscience, with notable contributions from Darzalex and Tremphya. Strategic initiatives included the acquisition of Firefly Bio to enhance its oncology pipeline and continued investments in MedTech innovations like the OTAVA robotic surgical system. 7% increase compared to the previous year.

Management expressed confidence in achieving double-digit growth by the end of the decade, driven by a diverse portfolio and disciplined execution. Full Transcript OPERATOR Good morning and welcome to Johnson & Johnson's second quarter 2026 earnings conference call. All participants will be in the listen-only mode until the question and answer session of the conference. This call is being recorded.

If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press Star zero to reach the operator. I will now turn the conference call over to Johnson & Johnson. You may begin.

Ryan Coors, Vice President of Investor Relations Hello everyone, this is Ryan Coors, Vice President of Investor Relations for Johnson & Johnson. I'm excited to be here today and to lead the investor relations team moving forward. Welcome to our company's review of business results for the second quarter of 2026 and our financial outlook for the full year. First, a few logistics.

As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website as well. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording.

They are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.

Moving to today's agenda, Joaquin Duato, our Chairman and CEO, will discuss our business performance and growth drivers. I will then review the second quarter sales and P&L results. Joe Walk, our CFO, will then close by sharing an overview of our capital allocation priorities and updated guidance for 2026. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, John Reed, Executive Vice President, Innovative Medicine Research and Development, and Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be joining us for Q&A.

To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes. With that, I will now turn the call over to Joaquin. Joaquin Duato, Chairman and CEO Thank you, Ryan, and welcome to your new role. I'm pleased to share the top-line results from our strong second quarter.

We said 2026 would be a year of accelerated growth and impact for Johnson & Johnson, and with to bid on the top and bottom line and raised guidance, we are delivering across oncology, immunology, neuroscience, cardiovascular surgery, and vision. The strength of our business is built on our unique combination of scientific expertise, scale, and disciplined execution. We have the strongest portfolio and pipeline in our 140-year history with 28 products and platforms that delivered more than a billion dollars in annual sales. 6%.

Excluding Stellara, we grew double digits in the quarter. With sales in the quarter of more than $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our company's 140-year history. We are pleased with the progress of our new launches, including Icotide in Lexo and Rybrebant, instilling confidence that momentum will accelerate into 2027 and beyond with line of sight to double-digit growth by the end of the decade. Icotide in particular has significant early launch momentum with uptake accelerating and performance outpacing competitors at comparable points in their launches.

Since launch, more than 10,000 patients have initiated therapy on Nicotide, underscoring their unmet need for patients seeking first-line systemic treatment with a unique combination of efficacy, safety, and the simplicity of a once-daily pill. 8% in the quarter with eight brands growing double digits. In oncology, our commitment to transform patient outcomes has never been stronger. We are on track to be the number one oncology company by 2030 with sales projected to exceed $50 billion.

Leading the way in Q2 is DarzaLex, the foundational treatment for multiple myeloma, which continues to be our larges